Dr. Nadia Khan, MD

Dr. Khan practices at Tufts Medical Center in Boston, Massachusetts, part of Tufts Medicine.

Dr. Khan's NPI, 1659531499, was assigned on June 16, 2008. Dr. Khan graduated from Temple University School of Medicine in 2003. Dr. Khan holds Illinois license 036169779.

Dr. Khan's primary practice is Tufts Medical Center, at 800 Washington Street, Boston, MA 02111 in Suffolk County. The practice phone is (617) 636-5000.

Dr. Khan's primary practice is Tufts Medical Center in Boston, Massachusetts, part of Tufts Medicine. Dr. Khan is also affiliated with Swedish First Hill Campus. The medical group on file is Pratt Medical Group, Inc. - General Medical Associates (General Internal Medicine). Dmand AI also links Dr. Khan to 1 more hospital, 1 group practice or clinic, 1 imaging center and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Khan practices, 5 sites in all. Vendor and product names are available with a free account.

Internal medicine is Dr. Khan's primary specialty in the NPI Registry, under taxonomy code 207RH0000X. The record also lists hematology. Dmand AI has Dr. Khan's licenses on file in 2 states: Illinois and Washington.

CMS data shows 183 Medicare services from Dr. Khan across 5 procedure codes in 2024, all of them office visits, for 118 Medicare patients. Medicare paid $17,377 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 118 Medicare patients who saw Dr. Khan in 2024. The largest group is 65 to 74, with 50 patients. 73% of them have high blood pressure, and 71% have high cholesterol. 14% are also on Medicaid. Their average risk score is 1.80, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Khan's median patient age at 64, with 60% women.

In 2024, Dr. Khan wrote 430 Medicare Part D claims for 66 patients. CMS names the drug for 293 of them, across 9 drugs with 11 or more claims each, at $2,608,125 in total drug cost. In 2023, CMS named 212 claims across 10 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 87 out of 100 for Dr. Khan for performance year 2024, reported as part of a group. Dr. Khan accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Khan as offering telehealth.

Dmand AI links 49 papers to Dr. Khan, published from 2016 to 2025. 2021 was the busiest year, with 10. The most frequent topics are Antineoplastic Combined Chemotherapy Protocols, Australia and Hodgkin Disease. Dr. Khan has published most often in J Natl Compr Canc Netw. Dr. Khan's most frequent co-authors are Brad Steven Kahl, MD, Jeremy S. Abramson, MD and Paolo F. Caimi, MD.

CMS Open Payments shows 130 general payments to Dr. Khan from 16 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 51% of the total. Genentech, Inc. paid the most, $64,673. It also lists 2 research payments totaling $450 in 2020.

Dr. Khan graduated from Temple University School of Medicine in 2003.